Min S. Lee

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

N. Meanwell, R. Colonno, Chaoqun Chen, 2012, Antimicrobial Agents and Chemotherapy.

A Small Molecule Inhibitor Selectively Induces Apoptosis in Cells Transformed by High Risk Human Papilloma Viruses

B. Beno, L. Schweizer, M. Lei, 2016, PloS one.

Cells transformed by PLC-gamma 1 overexpression are highly sensitive to clostridium difficile toxin A-induced apoptosis and mitotic inhibition.

Ho Kim, H. Nam, H. Seok, 2012, Journal of microbiology and biotechnology.

Development of a Chimeric Replicon System for Phenotypic Analysis of Ns3 Protease Sequences from HCV Clinical Isolates

P. Falk, A. Sheaffer, J. Friborg, 2011, Antiviral therapy.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.

Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir

Chaoqun Chen, P. Falk, A. Sheaffer, 2012, Antimicrobial Agents and Chemotherapy.

P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.

A. Good, N. Meanwell, R. Rajamani, 2018, Bioorganic & medicinal chemistry letters.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.